Immunai and AstraZeneca's $18 million AI collaboration aims to transform cancer drug development and enhance R&D strategies.Immunai Inc., a New York-based artificial intelligence (AI) and biotech firm, is collaborating with AstraZeneca. The partnership will provide Immunai with $18 million for its initial phase.

Immunai和阿斯利康1800万美元的人工智能合作旨在改变癌症药物的开发并加强研发策略。总部位于纽约的人工智能（AI）和生物技术公司Immunai Inc.正在与阿斯利康合作。该伙伴关系将为Immunai的初始阶段提供1800万美元。

This collaboration focuses on enhancing clinical decision-making, including dose selection and biomarker identification. Immunai will leverage its AI immune system model, the IDE, to improve clinical trial success rates. AstraZeneca may expand the collaboration’s length and scope after the initial phase.

这种合作的重点是加强临床决策，包括剂量选择和生物标志物鉴定。Immunai将利用其AI免疫系统模型IDE来提高临床试验成功率。在初始阶段之后，阿斯利康可能会扩大合作的长度和范围。

This initiative reflects a growing trend of using AI to transform clinical development processes and expedite access to innovative therapies for cancer patients.Collaboration Overview: Immunai’s AMICA and IDE for Breakthrough Cancer InsightsImmunai, an AI biotech company, has announced a multi-year collaboration with AstraZeneca.

合作概述：Immunai的AMICA和IDE for Breaking Cancer InsightsImmunai，一家人工智能生物技术公司，宣布与阿斯利康进行多年合作。

This partnership aims to enhance the development of oncology therapies through advanced data analysis. Under the terms of the agreement, AstraZeneca will provide Immunai with $18 million for the initial phase of this collaboration.“This collaboration is a natural progression of our successful work in advancing drug development in the fields of oncology and immunology,” said Noam Solomon, Ph.D., CEO of Immunai.

这种伙伴关系旨在通过先进的数据分析来促进肿瘤治疗的发展。根据协议条款，阿斯利康将为Immunai提供1800万美元，用于此次合作的初始阶段。Immunai首席执行官诺姆·所罗门（Noam Solomon）博士说：“这种合作是我们在推进肿瘤学和免疫学领域药物开发方面成功工作的自然进展。”。

“Bringing a drug to market is incredibly challenging, time consuming and expensive. Through this collaboration with AstraZeneca, we’re excited to leverage our AI-based engine the IDE™ to help make this process more efficient in bringing potential new therapies to patients.”The collaboration will leverage Immunai’s proprietary technologies, including its immune cell atlas, AMICA, and the Immunodynamics Engine (IDE).

“将药物推向市场极具挑战性、耗时且昂贵。通过与阿斯利康的合作，我们很高兴能够利用我们基于人工智能的引擎IDE™来帮助这一过程更有效地为患者带来潜在的新疗法。”该合作将利用Immunai的专有技术，包括其免疫细胞图谱、AMICA和免疫动力学引擎（IDE）。